Status:
RECRUITING
Guideline Oriented Approach To Lipid Lowering In Asia-Pacific
Lead Sponsor:
Stephen Nicholls
Collaborating Sponsors:
Amgen
Conditions:
Cardiovascular Diseases
Acute Coronary Syndrome
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Multinational, patient-level randomised, multi-phase standard-of-care control arm, parallel group, implementation study. Patients will be recruited during hospitalisation and be randomised to a multi...
Detailed Description
The study will be conducted over two phases. In phase I (0-6 months), participants randomized to 'early' will receive the intervention at baseline through 6 months, while those randomized to 'late' w...
Eligibility Criteria
Inclusion
- 18 years of age
- Admission for Type I myocardial infarction
Exclusion
- LDL \<1.4mmol/L at baseline
- Unable to provide contact details of primary care physician/general practitioner
- Unable to provide written informed consent.
- Unlikely to survive \>12 months
Key Trial Info
Start Date :
September 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT05325034
Start Date
September 15 2022
End Date
December 1 2026
Last Update
August 14 2025
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Illawarra Shoalhaven Local Health District
Wollongong, New South Wales, Australia, 2500
2
Cairns & Hinterland Hospital & Health Service
Cairns, Queensland, Australia, 4870
3
Flinders Medical Centre
Bedford Park, South Australia, Australia, 5042
4
Monash Health
Clayton, Victoria, Australia, 3800